Clinical data (from an international phase III study: NO16966) presented at the American Society of Clinical Oncology Gastrointestinal Symposium (ASCO GI) in Orlando, Florida suggest that XELOX (Xeloda® + oxaliplatin) is an effective alternative to the current standard treatment for advanced (metastatic) colorectal cancer - FOLFOX-4 (infused 5-FU/leucovorin + oxaliplatin).
XELOX, an abbreviation for a type of combination chemotherapy used to treat colorectal cancer, contains Roche’s Xeloda® (capecitabine), the only FDA-approved oral chemotherapy for metastatic breast cancer and metastatic colorectal cancer, plus oxaliplatin.
According to Professor Jim Cassidy, co-lead investigator for the study and Cancer Research UK Professor of Oncology and Chair of Medical Oncology, Beatson Oncology Centre, at the University of Glasgow, Scotland:
Find more details of the clinical data from the Roche press release."These important survival results continue to affirm our initial hypothesis that XELOX is a viable, effective alternative to the current standard of care for advanced colorectal cancer.
These data underscore the tremendous promise of combinations using cornerstone therapies such as Xeloda, and the potential benefit of adding Avastin to achieve greater progression-free survival."
ARe there studies for xelox for pancreatic cancer?
Thank you I need the studies for my father to get the txment
Posted by: Anonymous | May 2, 2007 9:08 PM | Permalink to Comment